VEGF deficit is involved in endothelium dysfunction in preeclampsia

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 30, Issue 3, 2010, Pages 370-374

  Zhou, Qiong ^a   Liu, Haiyi ^a   Qiao, Fuyuan ^a   Wu, Yuanyuan ^a   Xu, Jingjing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cell proliferation; Endothelium dysfunction; Monolayer barrier function; Nitric oxide; Preeclampsia

Indexed keywords

MESSENGER RNA; NITRIC OXIDE; SMALL INTERFERING RNA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PLACENTA; PREECLAMPSIA; PREGNANCY; UMBILICAL VEIN ENDOTHELIAL CELL;

ADULT; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NITRIC OXIDE; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956385134     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-010-0359-y     Document Type: Article

References (25)

1. Shah DM. Preeclampsia: new insights. Curr Opin Nephrol Hypertens, 2007, 16(3):213-220
2. Michiels C. Endothelial cell functions. J Cell Physiol, 2003, 196(3):430-443
3. Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract, 2007, 106(2):c72-81
4. Rabbani ML, Rogers PA. Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats. Reproduction, 2001, 122(1):85-90
5. Lyall F, Greer IA, Boswell F, et al. Suppression of serum vascular endothelial growth factor immuno reactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol, 1997, 104(2):223-228
6. Reuvekamp A, Velsing-Aarts FV, Poulina IE, et al. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclam psia. Br J Obstet Gynaecol, 1999, 106(10):1019-1022
7. Cunningham FG, Gant NF, Leveno KJ, et al. Hypertensive disorders in pregnancy. In: Williams obstetrics: Common complications of pregnancy. 21th ed. Authorized reprinting by Science Press, 2002, 569-570
8. Filleur S, Courtin A, Ait-Si-Ali S, et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogeni c thrombospondin-1 and slows tumor vascularization and growth. Cancer Res, 2003, 63(14):3919-3922
9. van Nieuw Amerongen GP, Vermeer MA, Negre-Aminou P, et al. Simvastatin improves disturbed end othelial barrier function. Circulation, 2000, 102(23):2803-2809
10. Tao J, Tu YT, Li JW, et al. Endogenous production of nitric oxide contributes to proliferation effect of vascular endothelial growth factor-induced malignant melanoma cell. Clin Exp Dermatol, 2006, 31(1):94-99
11. Zhang Y, He L, Zhou Y. Taspine isolated from Radix et Rhizoma Leonticis inhibits growth of human umbilical vein endothelial cell (HUVEC) by inducing its apoptosis. Phytomedicine, 2008, 15 (1-2): 112-119
12. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246(4935):1306-1309
13. Ziemer LS, Koch CJ, Maity A, et al. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia, 2001, 3(6):500-508
14. Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun, 2002, 291(4):908-914
15. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertens ion, and proteinuria in preeclampsia. J Clin Invest, 2003, 111(5):649-658
16. Tripathi R, Rath G, Jain A, et al. Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia. Ann Anat, 2008, 190(5):477-489
17. Polliotti BM, Fry AG, Saller DN, et al. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol, 2003, 101(6):1266-1274
18. Bussolati B, Dunk C, Grohman M, et al. Vascular endothelial growth factor receptor-1 modulates vascul ar endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol, 2001, 159(3):993-1008
19. Kitamoto Y, Takeya M, Tokunaga H, et al. Glomerular endothelial cells are maintained by vascular endothel ial growth factor in the adult kidney. Tohoku J Exp Med, 2001, 195(1):43-54
20. Sugimoto H, Hamano Y, Charytan D, et al. Neutrali zation of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem, 2003, 278(15):12605-12608
21. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003, 349(253):427-434
22. Kuenen BC, Levi M, Meijers JC, et al. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol, 2002, 22(9):1500-1505
23. Gilbert JS, Ryan MJ, LaMarca BB, et al. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol, 2008, 294: H541-550
24. Zhu H, Bunn HF. Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol, 1999, 115(2):239-247
25. Banyasz I, Szabo S, Bokodi G, et al. Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia. Mol Hum Reprod, 2006, 12(4):233-236